Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endocrine analytes in multiple-marker screening

G M Lambert-Messerlian1, J A Canick

  • 1Department of Pathology, Brown University School of Medicine, USA.

Clinics in Perinatology
|January 19, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-trimester screening for pre-eclampsia: estimated vs measured mean arterial pressure.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2022
Same author

Circulating cell free DNA testing: are some test failures informative?

Prenatal diagnosis·2014
Same author

Expression of inhibin/activin proteins and receptors in the human hypothalamus and basal forebrain.

Journal of neuroendocrinology·2012
Same author

Maintaining quality assurance for sonographic nuchal translucency measurement: lessons from the FASTER Trial.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2009
Same author

Inhibin A measurement using an automated assay platform.

Prenatal diagnosis·2008
Same author

First- and second-trimester Down syndrome screening markers in pregnancies achieved through assisted reproductive technologies (ART): a FASTER trial study.

Prenatal diagnosis·2006
Same journal

Breathing Physiology into the Art of Neonatal Respiratory Care.

Clinics in perinatology·2026
Same journal

The Science and Art of Neonatal Respiratory Care.

Clinics in perinatology·2026
Same journal

Ex Utero Artificial Womb Support: Promising Future for Extremely Preterm Infants.

Clinics in perinatology·2026
Same journal

Advances in the Use of Cell-Based Therapies for Prevention of Bronchopulmonary Dysplasia.

Clinics in perinatology·2026
Same journal

Evaluation and Management of Genetic Respiratory Disorders Presenting as Hypoxemic Respiratory Failure in the Newborn Infant.

Clinics in perinatology·2026
Same journal

Modern Surfactant Delivery Methods with a Focus on Implementation of Surfactant Administration Through Laryngeal and Supraglottic Airways.

Clinics in perinatology·2026
See all related articles

Prenatal serum screening detects birth defects by measuring altered placental and fetal hormones in maternal blood. Advances like the four-marker test are improving accuracy and changing screening practices.

Area of Science:

  • Biochemistry
  • Genetics
  • Obstetrics

Background:

  • Prenatal serum screening relies on detecting altered placental and fetal secretory products in maternal blood.
  • Altered hormone levels in maternal serum are associated with fetal chromosomal abnormalities, though the underlying pathophysiology is often unclear.
  • Current screening methods include second-trimester triple-marker (AFP, uE3, hCG) and four-marker (adding inhibin A) tests.

Purpose of the Study:

  • To review the principles and advancements in prenatal serum screening.
  • To discuss the transition towards more accurate and potentially earlier screening methods.

Main Methods:

  • Review of existing literature on prenatal serum screening markers.
  • Analysis of the performance of current screening tests (triple- and four-marker).

Related Experiment Videos

Main Results:

  • Maternal serum levels of specific hormones are altered in pregnancies with certain birth defects.
  • The four-marker test demonstrates improved performance over the triple-marker screening.
  • Emerging first-trimester screening and new second-trimester markers are anticipated.

Conclusions:

  • Prenatal serum screening is evolving with improved marker panels and potential for earlier detection.
  • Future screening practices may be significantly impacted by these advancements.